Skip to Content

Label Changes for:

Brilinta (ticagrelor) 90 mg Tablets

January 2013

Changes have been made to the CONTRAINDICATIONS and ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)


January 2013


4.4 Hypersensitivity
  • BRILINTA is contraindicated in patients with hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product [see Adverse Reactions (6.2)]


6.2 Postmarketing Experience
  • The following adverse reactions have been identified during post-approval use of BRILINTA. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
  • Immune system disorders – Hypersensitivity reactions including angioedema [see Contraindications (4.4)]


Who should not take Brilinta? the following bullet was added:

  • "are allergic to ticagrelor or any of the ingredients in BRILINTA. See the end of this Medication Guide for a list of ingredients in BRILINTA.”